Molecular Targeted Therapy

"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.

Descriptor ID	D058990
MeSH Number(s)	E02.319.574
Concept/Terms	Molecular Targeted Therapy Molecular Targeted Therapy Molecular Targeted Therapies Targeted Therapies, Molecular Targeted Therapy, Molecular Therapies, Molecular Targeted Therapy, Molecular Targeted Targeted Molecular Therapy Molecular Therapies, Targeted Molecular Therapy, Targeted Targeted Molecular Therapies Therapies, Targeted Molecular Therapy, Targeted Molecular

Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Molecular Targeted Therapy [E02.319.574]

Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in this website by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.

Bar chart showing 287 publications over 16 distinct years, with a maximum of 35 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	3	3	6
2011	4	17	21
2012	7	9	16
2013	7	17	24
2014	6	21	27
2015	10	16	26
2016	5	23	28
2017	8	27	35
2018	4	22	26
2019	10	13	23
2020	8	12	20
2021	9	11	20
2022	1	4	5
2023	0	1	1
2024	2	6	8
2025	1	0	1

Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.

Podany EL, Foffano L, Gerratana L, Medford AJ, Clifton K, Tapiavala S, Velimirovic M, Lipsyc-Sharf M, Reduzzi C, Bubie A, Putur A, Ademuyiwa FO, Puglisi F, Gradishar WJ, Ma CX, Bardia A, Cristofanilli M, Davis AA. Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer. JAMA Netw Open. 2025 02 03; 8(2):e2461899.

View in: PubMed
Tolu SS, Viny AD, Amengual JE, Pro B, Bates SE. Getting the right combination to break the epigenetic code. Nat Rev Clin Oncol. 2025 Feb; 22(2):117-133.

View in: PubMed
Leventhal J, Madiedo ASA, Andriessen A, Choi JN, Ho A, McLellan B, Mitchell E, Lacouture M. INDIVIDUAL ARTICLE: USCOM IV Algorithm for the Prevention and Management of Targeted Therapy-Related Cutaneous Adverse Events. J Drugs Dermatol. 2024 Dec 01; 23(12):436613s3-436613s14.

View in: PubMed
Toracchio L, Carrabotta M, Mancarella C, Morrione A, Scotlandi K. EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities. Int J Mol Sci. 2024 Nov 13; 25(22).

View in: PubMed
Vlachou E, Hoffman-Censits J, Singla N. The biologic landscape and therapeutic implications of upper tract urothelial cancer. Curr Opin Urol. 2025 Jan 01; 35(1):89-95.

View in: PubMed
Menssen AJ, Hudson CA, Alonzo T, Gerbing R, Pardo L, Leonti A, Cook JA, Hsu FC, Lott LL, Dai F, Fearing C, Ghirardelli K, Hylkema T, Tarlock K, Loeb KR, Kolb EA, Cooper T, Pollard J, Wells DA, Loken MR, Aplenc R, Meshinchi S, Brodersen LE. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. Haematologica. 2024 Oct 01; 109(10):3182-3193.

View in: PubMed
Noll D, Kehr D, Most P, Ritterhoff J. S100A1: a promising therapeutic target for heart failure. Expert Opin Ther Targets. 2024 Apr; 28(4):233-236.

View in: PubMed
Eturi A, Bhasin A, Zarrabi KK, Tester WJ. Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma. Molecules. 2024 Apr 22; 29(8).

View in: PubMed
Friedman JS, Durham BH, Reiner AS, Yabe M, Petrova-Drus K, Dogan A, Pulitzer M, Busam KJ, Francis JH, Rampal RK, Ulaner GA, Reddy R, Yeh R, Hatzoglou V, Lacouture ME, Rotemberg V, Mazor RD, Hershkovitz-Rokah O, Shpilberg O, Goyal G, Go RS, Abeykoon JP, Rech K, Morlote D, Fidai S, Gannamani V, Zia M, Abdel-Wahab O, Panageas KS, Rosenblum MK, Diamond EL. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy. Br J Haematol. 2024 Jul; 205(1):127-137.

View in: PubMed
Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023 06; 20(6):349-365.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement